Showing 981 - 1,000 results of 1,840 for search '"clinical researcher"', query time: 0.11s Refine Results
  1. 981
  2. 982
  3. 983
  4. 984
  5. 985
  6. 986
  7. 987
  8. 988
  9. 989
  10. 990
  11. 991

    Serum Pharmacochemistry and Network Pharmacology Reveal Active Compounds and Mechanisms of the Huaxian Formula in Alleviating Radiation-Induced Pulmonary Fibrosis by Gong C, Chen J, Zou P, Fang Z, Quan L, Wang J, Yin J, Lin B, Lang J, Chen M

    Published 2025-01-01
    “…CuiCui Gong,1– 3 Junyang Chen,2 Pingjin Zou,2 Zengyi Fang,2 Li Quan,1– 3 Jing Wang,2,4 Jie Yin,2,5 Bing Lin,1 Jinyi Lang,1– 5 Meihua Chen2,3 1School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610032, People’s Republic of China; 2Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610041, People’s Republic of China; 3Institute of Integrated Traditional Chinese and Western Medicine Cancer Research, Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, People’s Republic of China; 4Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 5School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 611731, People’s Republic of ChinaCorrespondence: Jinyi Lang, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610032, People’s Republic of China, Email langjy610@163.com Meihua Chen, Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610041, People’s Republic of China, Email chenmeihua@scszlyy.org.cnPurpose: Radiation-induced pulmonary fibrosis (RIPF) is a serious complication of radiotherapy that lacks effective treatment options. …”
    Get full text
    Article
  12. 992

    Myofibrillogenesis Regulator-1 in Smooth Muscle Cells Modulates Inflammation Signaling Pathways via Regulating ROCK1 Ubiquitination and Degradation to Impact Aortic Dissection by Yin H, Li X, Lu D, Zhao X, Yang Z, Wang Z, Xu F, Chen Y, Li C

    Published 2025-02-01
    “…Hang Yin,1– 5,* Xiaoxing Li,6,* Dazhou Lu,1– 5,* Xin Zhao,7,* Zeyu Yang,1– 5 Zerui Wang,1– 5 Feng Xu,1– 5 Yuguo Chen,1– 5 Chuanbao Li1– 5 1Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 2Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 3Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 4Shandong Key Laboratory: Magnetic Field-Free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 5NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, People’s Republic of China; 6Department of Geriatrics, Qilu Hospital, Shandong University, Jinan, Shandong, People’s Republic of China; 7Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuanbao Li; Yuguo Chen, Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, People’s Republic of China, Email bao2460@126.com; chen919085@sdu.edu.cnBackground: Aortic dissection (AD) is a life-threatening cardiovascular emergency and currently lacks effective drug treatment. …”
    Get full text
    Article
  13. 993

    Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

    Published 2025-02-01
    “…Hao Su,1,* Xiao Shang,1,* Hongruo Liu,2 Yutong Wang,1 Yang Yu,3 Yanhua Xu,4 Kui Jiang,2,* Fengzhi Feng1,* 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 3Department of Obstetrics and Gynecology, Xing’an League People’s Hospital, Xing’an League, Inner Mongolia, People’s Republic of China; 4Department of Obstetrics and Gynecology, Jinan Maternity and Child Health Care Hospital, Jinan, Shandong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fengzhi Feng, Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Dong Cheng District, Beijing, 100730, People’s Republic of China, Email fengfz1969@sina.com Kui Jiang, Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116023, People’s Republic of China, Email jk0411@163.comPurpose: Therapeutic options for patients with platinum-resistant ovarian cancer (PROC) remain a major unmet need. …”
    Get full text
    Article
  14. 994
  15. 995
  16. 996
  17. 997
  18. 998
  19. 999
  20. 1000